Jci_page_head_homepage_01 Jci_page_head_homepage_02
Carmela De Santo, Mariolina Salio, S. Hajar Masri, Laurel Yong-Hwa Lee, Tao Dong, Anneliese O. Speak, Stefan Porubsky, Sarah Booth, Natacha Veerapen, Gurdyal S. Besra, Hermann-Josef Gröne, Frances M. Platt, Maria Zambon, Vincenzo Cerundolo
Published in Volume 118, Issue 12
J Clin Invest. 2008; 118(12):4036–4048 doi:10.1172/JCI36264
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 7
Inhibition of T cell proliferation by MDSCs purified from IAV-infected individuals.

CD11b+ cells were bead purified from PBLs derived from either IAV-infected individuals (AC) or healthy donors (D and E). All donors were bled twice. For donors 1, 2, and 3, the first blood sample was collected before the clinical symptom onset, while the second blood sample was collected within 30–60 days after the acute respiratory illness. Donors 4 and 5 did not have any respiratory illness within the time frame of the collection of the 2 blood samples. Irradiated purified CD11b+ cells were then added to allogenic PBLs and incubated with allogeneic irradiated DCs. Purified CD11b+ cells were either untreated (black bars) or treated with either α-GalCer (100 ng/ml) in the presence of iNKT cells at a MDSC/iNKT ratio of 1:0.25 (white bars) or L-NMMA and NOHA (gray bars). The data are expressed as described in Methods. Addition of either iNKT cells or L-NMMA and NOHA to the alloreactive PBLs in the absence of CD11b+ cells did not affect T cell proliferation (data not shown). The ratio of irradiated DCs to purified irradiated CD11b+ cells was 1:1.